Irbesartan/Hydrochlorothiazide Viatris

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hydrochlorothiazide Viatris, is an angiotensin II receptor blocker / thiazide diuretic presented as a tablet for oral use. It combines an ARB with a thiazide diuretic to provide complementary blood‑pressure reduction and is prescribed for the treatment of hypertension in adult patients.

GNH USA supplies Irbesartan/Hydrochlorothiazide Viatris as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide in accordance with regulatory standards and quality assurance and reliable procedures.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to lower blood pressure.

- Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Resistant hypertension: adds a diuretic effect to improve control when an ARB alone is insufficient. - Hypertension with fluid retention: promotes diuresis to manage volume overload while lowering blood pressure.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Increased urination or nocturia. - Mild electrolyte disturbances such as low potassium. - Fatigue or weakness. - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension leading to fainting. - Acute kidney injury or worsening renal function. - Hyperkalemia, particularly when combined with potassium‑sparing agents. - Allergic reactions including rash, angioedema, or anaphylaxis. - Pancreatitis. - Significant liver enzyme elevations.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: check serum creatinine and eGFR periodically. - Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. - Caution in elderly patients: start at lower doses due to increased sensitivity. - Pregnancy and lactation: avoid use unless clearly indicated, as safety data are limited. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines; careful review is recommended.

Major Interactions (Avoid): - Aliskiren combined with an ARB: risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function. - Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood‑pressure lowering, monitor for hypotension. - Other thiazide or loop diuretics: risk of excessive diuresis and electrolyte loss. - Antidiabetic agents: blood‑glucose may improve, requiring dose adjustment. - CYP3A4 inhibitors (e.g., ketoconazole): may increase irbesartan plasma concentrations. - Antihypertensive combinations (beta‑blockers, calcium channel blockers): monitor for additive hypotensive effect.